News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
US business grew by +12.8% YoY
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
